REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 9th, 2013 • Amarantus Bioscience Holdings, Inc. • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of September 3, 2013, between Amarantus BioScience Holdings, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
COMMON STOCK PURCHASE WARRANT Amarantus BioScience Holdings, Inc.Security Agreement • September 9th, 2013 • Amarantus Bioscience Holdings, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after September ___, 2013 (the “Initial Exercise Date”) and on or prior to the close of business on the three year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Amarantus BioScience Holdings, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 9th, 2013 • Amarantus Bioscience Holdings, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of September 3, 2013, between AMARANTUS BIOSCIENCE HOLDINGS, INC., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
8% ORIGINAL ISSUE DISCOUNT SENIOR CONVERTIBLE DEBENTURE DUE SEPTEMBER ___, 2014Convertible Security Agreement • September 9th, 2013 • Amarantus Bioscience Holdings, Inc. • Pharmaceutical preparations • New York
THIS 8% ORIGINAL ISSUE DISCOUNT SENIOR CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued 8% Original Issue Discount Senior Convertible Debentures of Amarantus BioScience Holdings, Inc., a Nevada corporation, (the “Company”), having its principal place of business at 675 Almanor Ave., Sunnyvale, CA 94085, designated as its 8% Original Issue Discount Senior Convertible Debenture due September ___, 2014 (this debenture, the “Debenture” and, collectively with the other debentures of such series, the “Debentures”).
